WellPATH-PREVENT: A Mobile Intervention for Middle-Aged and Older Adults Hospitalized for Suicidal Ideation or Attempt

Conditions

• Depression
• Suicidal Ideation
• Suicide, Attempted

Eligibility Criteria

Sex

ALL

Age

50 Years - 90 Years

Healthy Volunteers

Not accepted

Interventions

• WellPATH-PREVENT — BEHAVIORAL
  WellPATH-PREVENT is a novel personalized, easy to use, mainly stand-alone mobile intervention which focuses on the exclusive use of the WellPATH tablet app and includes training meetings during hospitalization, and virtual post-discharge coaching meetings. The meetings aim to: a) identify stressors and triggers of negative emotions associated with increased suicidal ideation or with suicidal behavior; b) develop techniques (text or video) to increase cognitive reappraisal ability; c) incorporate the techniques into the WellPATH app and promote the use of WellPATH during stressful incidents, triggers of negative emotions, or scheduled brief training sessions; and d) remotely update the triggers, negative emotions, and techniques in the app.
• Optimized WellPATH-PREVENT — BEHAVIORAL
  The Optimized WellPATH-PREVENT intervention will be as described above, but based on the results of the Proof-of-Concept (R61) Phase, an expert committee will help select the duration (6 or 12 weeks) that shows greater improvement in cognitive reappraisal.

Study Details

The goal of this project is to test whether WellPATH-PREVENT (a novel, mobile psychosocial intervention) improves a specific aspect of emotion regulation, i.e., cognitive reappraisal ability, and reduces suicide risk in middle-aged and older adults (50-90 years old) who have been discharged after a suicide-related hospitalization (i.e. for suicidal ideation or suicide attempt).

Key Dates

Start date

Apr 22, 2022

Status verified

Oct 2025

Primary completion

Sep 30, 2026

Completion

Sep 30, 2026

Study Design

Enrollment

115 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Arms

• Experimental: Proof-of-Concept WellPATH-PREVENT (R61)
• Experimental: Optimized WellPATH-PREVENT (R33)
• No Intervention: Attention Control Usual Care (R33)
  The AC-UC group will parallel the delivery of the WellPATH-PREVENT intervention and will also include: a) meetings during hospitalization: a non-clinical member of the team will present the control tablet and explain its use; b) scheduled or requested meetings through zoom: to parallel the delivery of WellPATH-PREVENT. The tablet will still have a link to schedule a meeting with a non-clinician member of the team. The meetings will focus on issues that the patient may have in using the tablet. There will not be any therapeutic or psychological interaction between participants in the control group and the team. The experimental and the control group will also be under usual outpatient care, which is arranged during the hospitalization by the inpatient treatment team.

Primary Outcome Measure

Change in Event Related Potential - Late Positive Potential (ERP/LPP) - R61 [ Time Frame: Study Entry, Week 6, Week 12 ]

Central Contacts

• Dimitris Kiosses, PhD
  914-997-4381
  [email protected]
• Laurie Evans, MS
  914-682-9100
  [email protected]

Locations (2)

Find similar trials in New York, NY

Related Studies

• Suicide Treatment Alternatives for Teens
  Recruiting · Children's Hospital Medical Center, Cincinnati · Glen Oaks, New York
• Lay-Delivered Behavioral Activation in Senior Centers
  Recruiting · University of Washington · Brandon, Florida
• Safe Mothers, Safe Children Initiative
  Recruiting · New York University · New York, New York
• A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
  PHASE3 · Recruiting · AbbVie · Bentonville, Arkansas